

From: [Stephen Routledge](#)
To: [PMPRB Consultations / Consultations CEPMB](#)
Subject: PMPRB Draft Guidelines Consultation
Date: February 14, 2020 5:02:53 PM
Attachments: [image474803.png](#)
[image668867.png](#)
[image965310.png](#)
[image598599.png](#)
[image576539.png](#)
[image143843.png](#)

Good afternoon,

Thank you for the opportunity to review the guidelines and backgrounder. On behalf of CPSI, please consider the following feedback:

Unacceptable price increases can make medications unaffordable to patients resulting in sudden or unexpected change to their medication regimen. Changes such as inappropriate substitutions or missed dosages can put patients at increased risk of harmful medication incidents and/or unintended drug interactions. Canadians expect that patient safety is not compromised due to financial barriers of medication costs. The Canadian Patient Safety Institute recommends that the Draft Guidelines for the revised *Patented Medicines Regulations* ensure that medication safety is carefully considered when the regulations come into force in July.

We're looking forward to the next stage of the consultation and would be happy to provide additional feedback throughout the process.

Best regards,
Steve



Stephen Routledge, MPH
Senior Program Manager, Canadian Patient Safety Institute
m: 780-616-5320
SRoutledge@cpsi-icsp.ca | www.patientsafetyinstitute.ca

Patient Safety RightNow
A row of five social media icons: Twitter, LinkedIn, YouTube, Facebook, and Instagram.

Help **#ConquerSilence** and prevent patient harm in our healthcare system. Visit conquersilence.ca